A Tata memorial centre led study concludes that 50% oral cancer patients die within a year of diagnosis

INDIA – The first-of-its-kind study on the ‘cost of illness analysis of oral cancer’, conducted by Tata Memorial Centre in Mumbai, reveals that half of oral cancer patients in India die within a year of diagnosis and are aged between 30-50 years. The study was conducted on 100 consecutive oral cancer patients who sought treatment at the facility between October 2019 and March 2020 and pointed out that most of the patients who receive some form of treatment are left unemployed hence they become an economic burden to their families.…

Read More

BioNTech’s BNT111 phase 2 clinical trial makes progress as patient with advanced Melanoma treated

GERMANY – BioNTech, a German pharmaceutical company, has announced that the first patient has been treated in its BNT111 phase 2 cancer medication trial. Currently, the study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control or can be refereed to hyperpigmentation. BNT111…

Read More

Sun Pharma announces settlement of patent litigation with Celgene in US

USA – Sun Pharmaceutical Industries today announced settlement of patent litigation for generic Revlimid (lenalidomide) in the US. Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS), cancer forms that fall under leukemia. Multiple myeloma is a relatively uncommon cancer. In the United States, the lifetime risk of getting multiple myeloma is 1 in 132 (0.76%). The American Cancer Society’s estimates for multiple myeloma in the United States for 2021 are, About 34,920 new cases will be…

Read More

Roche launches first cancer treatment center in Ghana for effective cancer care

GHANA – Roche, a global pioneer in pharmaceuticals and diagnostics and the leading provider of cancer treatments globally, has launched a cancer treatment center at the Cape Coast Teaching Hospital (CCTH) for accessible and effective cancer care in the Region and beyond. It is the first of three cancer centers to be established by Roche, in collaboration with the Ministry of Health to provide and promote effective and efficient cancer care and bring treatment closer to the door steps of people affected with the disease. The launch coincided with the…

Read More

Construction company JBN to construct first state-owned cancer and cadio-vascular center

NIGERIA – Julius Berger Nigeria Plc (JBN), a construction company, has secured contract to build Nigeria’s first state-owned cancer and cadio-vascular diseases diagnostic and treatment centre in Port Harcourt, Rivers State. Rivers State Governor, Nyesom Wike, said the multi-billion naira project is for a 14-month completion period, emphasising that JBN, would complete and deliver the project for inauguration as scheduled. “We chose Julius Berger to help us build it not only well, but also successfully within its scheduled completion time as experience have taught us the company always do with projects they…

Read More

Al Jalila Foundation receives USD 59.8 million donor funding to establish Hamdan Bin Rashid Cancer Charity Hospital

DUBAI – Al Jalila Foundation, a member of the Mohammed bin Rashid Al Maktoum Global Initiatives, announced that it has already raised over 59 million USD to establish the Hamdan Bin Rashid Cancer Charity Hospital to help cancer patients in need. The UAE’s first charity hospital will accelerate the UAE’s efforts to be a leader in cancer care and a pioneer in medical innovation shaping the future of medicine. Al Jalila Foundation is investing AED750 million in the 250-bed hospital spanning 50,000 square metres, which will be built in two…

Read More

Biosphere tenant Iksuda Therapeutics raises $47m to reinforce Antibody Drug Conjugate pipeline

UK – UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers. Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase clinical trials, and will also be used to fast-track its earlier-stage programs. Currently, the company’s drug development pipeline is focused on the improved safety and efficacy…

Read More

FDA approves targeted therapy for KRAS lung cancer mutation

U.S – The Food and Drug Administration has approved a targeted therapy drug by AMGEN INC for non-small cell lung cancer with a specific mutation in a gene known as KRAS. The drug, sotorasib, which will be sold under the brand name Lumakras, shrank tumours with the KRAS mutation in around 36 percent of patients in clinical trials. This medication is designed to target a gene mutation known as KRAS G12C that occurs in about 13 percent of non-small cell lung cancers, or NSCLC, the most common type of lung…

Read More